Sarepta Therapeutics(NASDAQ) SRPT

Sarepta Therapeutics, Inc. helps people with rare genetic diseases. Its medicines help bodies produce proteins to keep muscles healthy and strong. These treatments focus on patients with Duchenne muscular dystrophy.

Genetic Medicines for Muscle Health

• PMO Products: EXONDYS 51, VYONDYS 53, and AMONDYS 45; use specialized RNA chemistry to help the body skip over genetic errors in Duchenne muscular dystrophy, a muscle-wasting disease.
• ELEVIDYS: Gene therapy that delivers functional genetic instructions to muscle cells; approved for ambulatory patients with Duchenne muscular dystrophy and carries a safety warning for liver risks.
• SRP-9003: Investigational gene therapy for Limb-girdle muscular dystrophy, a group of diseases causing muscle weakness in the hips and shoulders; currently in Phase 3 clinical trials.
• RNAi Programs: Research-stage therapies designed to silence harmful genes; developed in partnership with Arrowhead Pharmaceuticals for various neuromuscular and neurodegenerative disorders.

Strategic Shifts and Global Partners

• Partnered with Roche in a global collaboration to commercialize ELEVIDYS outside the U.S., expanding the company's international reach.
• Entered a multi-program agreement with Arrowhead Pharmaceuticals in 2025 to develop new RNA-targeted treatments for rare diseases.
• Announced a strategic restructuring in July 2025 to reduce operating expenses and focus resources on the most promising drug candidates.
• Expanded gene therapy manufacturing capacity through long-term partnerships with specialized contract manufacturers Catalent and Aldevron.

Precision Engineering for Rare Diseases

Sarepta uses multiple technological platforms to address rare genetic mutations. The company maintains a distribution network of specialty pharmacies and logistics providers to deliver fragile genetic treatments directly to hospitals and patients.

The Financial Scorecard

• Total revenues were $1.1 billion for the six-month period ended June 30, 2026, down 17% year over year.
• Research and development expenses were $245.2 million for the six-month period ended June 30, 2026, down 75% year over year.
• Collaboration and other revenues reached $472.9 million for the six-month period ended June 30, 2026, up 104% year over year.
• Cash, cash equivalents, restricted cash, and investments totaled $945.0 million as of June 30, 2026.

Evolving Toward Financial Stability

Sarepta has transitioned from a research-focused firm to a commercial company with four approved genetic therapies. Its focus on restructuring and strategic partnerships aims to balance high development costs with long-term financial stability.